SEC Form 4Coverage since Aug 15, 2025Open-market trades only
$CYTK insider trading
Over the last 12 months, Cytokinetics insiders reported no purchases and 76 sales totaling $43.0M across SEC Form 4 filings. 91% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $43.0M 76 events
- Events · 12m
- 76 Form 4 filings, grouped
- Insiders · 12m
- 9 distinct reporters
- 10b5-1 share
- 91% of events, not dollars
Side
Price · $CYTK · 3Mvia TradingView
Top insiders · 12m
Callos AndrewEVP, Chief Commercial Officer21× · $15.3M
Malik Fady IbrahamEVP Research & Development18× · $4.1M
Blum Robert IPresident & CEO16× · $9.1M
Kaye Edward M. MD—6× · $3.5M
Lee SungEVP, Chief Financial Officer5× · $5.7M
All insider trades
50 of 78 events
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Malik Fady IbrahamEVP Research & Development · O | ▼ Sale | 3,500 | $75.82 | $265K | -2.2% | plan |
| Aug 10, 2026 | Blum Robert IPresident & CEO · O·D | ▼ Sale | 7,500 | $76.76 | $576K | -1.9% | plan |
| Jul 30, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 14,000 | $79.88 | $1.1M | -19.3% | plan |
| Jul 27, 2026 | Blum Robert IPresident & CEO · O·D | ▼ Sale | 7,500 | $80.87 | $607K | -1.9% | plan |
| Jul 21, 2026 | Malik Fady IbrahamEVP Research & Development · O | ▼ Sale | 3,500 | $80.59 | $282K | -2.2% | plan |
| Jul 13, 2026 | Blum Robert IPresident & CEO · O·D | ▼ Sale | 7,500 | $82.02 | $615K | -1.9% | plan · 2 tranches |
| Jul 7, 2026 | Malik Fady IbrahamEVP Research & Development · O | ▼ Sale | 3,500 | $86.62 | $303K | -2.2% | plan |
| Jul 1, 2026 | Blum Robert IPresident & CEO · O·D | ▼ Sale | 7,500 | $84.92 | $637K | -1.9% | plan |
| Jul 1, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 15,000 | $85.8 | $1.3M | -20.4% | plan |
| Jul 1, 2026 | Lee SungEVP, Chief Financial Officer · O | ▼ Sale | 1,112 | $87.79 | $98K | -1.7% | plan |
| Jun 29, 2026 | Lee SungEVP, Chief Financial Officer · O | ▼ Sale | 3,134 | $85 | $266K | -4.7% | plan |
| Jun 24, 2026 | Lee SungEVP, Chief Financial Officer · O | ▼ Sale | 38,730 | $82.3 | $3.2M | -38% | plan |
| Jun 23, 2026 | Malik Fady IbrahamEVP Research & Development · O | ▼ Sale | 3,500 | $79.51 | $278K | -2.2% | plan |
| Jun 15, 2026 | Blum Robert IPresident & CEO · O·D | ▼ Sale | 7,500 | $70.46 | $528K | -1.9% | plan |
| Jun 9, 2026 | Malik Fady IbrahamEVP Research & Development · O | ▼ Sale | 3,500 | $67.98 | $238K | -2.2% | plan |
| Jun 1, 2026 | Kaye Edward M. MDD | ▼ Sale | 2,933 | $76.09 | $223K | -22.2% | plan |
| Jun 1, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 15,000 | $74.08 | $1.1M | -20.4% | plan |
| Jun 1, 2026 | PARSHALL B LYNNED | ▼ Sale | 5,000 | $74.08 | $370K | -24.1% | plan |
| May 27, 2026 | Blum Robert IPresident & CEO · O·D | ▼ Sale | 7,500 | $77.21 | $579K | -1.9% | plan |
| May 5, 2026 | Malik Fady IbrahamEVP Research & Development · O | ▼ Sale | 3,500 | $77.37 | $271K | -2.2% | plan |
| May 5, 2026 | WIERENGA WENDELLD | ▼ Sale | 4,032 | $75 | $302K | -11% | plan |
| May 5, 2026 | Lee SungEVP, Chief Financial Officer · O | ▼ Sale | 23,906 | $76.87 | $1.8M | -27.4% | plan |
| May 5, 2026 | HENDERSON JOHN TD | ▼ Sale | 20,000 | $75.97 | $1.5M | -21% | plan |
| May 5, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 11,333 | $77.25 | $875K | -16.2% | plan |
| May 1, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 15,857 | $65 | $1.0M | -21.3% | plan |
| Apr 30, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 15,000 | $63.26 | $949K | -20.4% | plan |
| Apr 29, 2026 | Blum Robert IPresident & CEO · O·D | ▼ Sale | 7,500 | $59.62 | $447K | -1.8% | plan |
| Apr 21, 2026 | Malik Fady IbrahamEVP Research & Development · O | ▼ Sale | 3,500 | $65.69 | $230K | -2.2% | plan |
| Apr 15, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 7,449 | $66.02 | $492K | -11.3% | plan |
| Apr 15, 2026 | Blum Robert IPresident & CEO · O·D | ▼ Sale | 7,500 | $65.38 | $490K | -1.8% | plan |
| Apr 7, 2026 | Malik Fady IbrahamEVP Research & Development · O | ▼ Sale | 4,500 | $65.11 | $293K | -2.8% | plan · 2 tranches |
| Apr 1, 2026 | Blum Robert IPresident & CEO · O·D | ▼ Sale | 7,500 | $66.63 | $500K | -1.7% | plan |
| Mar 31, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 3,639 | $65 | $237K | -5.2% | plan |
| Mar 18, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 1,930 | $62.07 | $120K | -2.4% | plan |
| Mar 17, 2026 | Lee SungEVP, Chief Financial Officer · O | ▼ Sale | 4,935 | $62.15 | $307K | -5.4% | — |
| Mar 17, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 8,542 | $62.15 | $531K | -10.7% | 2 tranches |
| Mar 17, 2026 | Malik Fady IbrahamEVP Research & Development · O | ▼ Sale | 12,033 | $62.15 | $748K | -7.3% | 2 tranches |
| Mar 17, 2026 | Blum Robert IPresident & CEO · O·D | ▼ Sale | 36,601 | $62.15 | $2.3M | -7.8% | 2 tranches |
| Mar 16, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 1,709 | $61.03 | $104K | -3.6% | plan |
| Mar 9, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 2,582 | $60.72 | $157K | -5.1% | — |
| Mar 9, 2026 | Malik Fady IbrahamEVP Research & Development · O | ▼ Sale | 2,907 | $60.72 | $177K | -2.1% | — |
| Mar 9, 2026 | Blum Robert IPresident & CEO · O·D | ▼ Sale | 7,931 | $60.72 | $482K | -2% | — |
| Mar 5, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 26,000 | $61.87 | $1.6M | -34% | plan · 2 tranches |
| Mar 2, 2026 | PARSHALL B LYNNED | ▼ Sale | 5,000 | $61.21 | $306K | -21.8% | plan |
| Mar 2, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 886 | $61.62 | $55K | -1.7% | plan |
| Feb 5, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 15,000 | $61.93 | $929K | -22.9% | plan |
| Feb 2, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 886 | $62.1 | $55K | -1.7% | plan |
| Jan 5, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 15,000 | $60.28 | $904K | -22.9% | plan |
| Jan 2, 2026 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 1,798 | $62.62 | $113K | -3.4% | plan · 2 tranches |
| Dec 29, 2025 | Callos AndrewEVP, Chief Commercial Officer · O | ▼ Sale | 1,809 | $62.44 | $113K | -3.4% | plan |
Every $CYTK filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Cytokinetics filings can reach your inbox instead.
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $CYTK feed.